2016 American Transplant Congress
Hepatocellular Carcinoma Decreases Chance of Successful HCV Therapy in the Current Era.
Gastroenterology and Hepatology, Northwestern University, Chicago, IL.
Background: The efficacy of direct acting antiviral agents (DAA) for hepatitis C (HCV) in patients with hepatocellular carcinoma (HCC) is limited. We hypothesized that virology…2016 American Transplant Congress
The BEST Trial: A Prospective Randomized Trial of Belatacept-Based, CNI- and Corticosteroid-Free Immunosuppression.
Efficacy of CNI- and corticosteroid-free immunosuppressive regimens has not been demonstrated in large, multicenter trials. BEST (Belatacept-based Early Steroid Withdrawal Trial) (NCT 01729494) compares 2…2016 American Transplant Congress
Impact of Early Calcineurin Inhibitor Withdrawal on Renal Function and Urinary Protein Excretion: 24 Month Analyses of the ELEVATE Study.
Background: Proteinuria is a biomarker which helps in predicting graft outcomes in kidney transplant recipients (KTxRs). The ELEVATE study was designed to determine whether an…2016 American Transplant Congress
TRANSFORM: A Modern Approach to Evaluate Long-Term Outcomes of Everolimus with Reduced-Calcineurin Inhibitors in De Novo Kidney Transplant Recipients[mdash]Baseline Characteristics.
Purpose: Acute rejection and poor graft function are two major risk factors for allograft failure in kidney transplant (KTx) recipients (KTxR). Although, graft survival and…2016 American Transplant Congress
Relationship Between Clinical Events and Everolimus Exposure at 12 Months in De Novo Renal Transplant Recipients.
We assessed the incidence of post-transplant biopsy-proven acute rejection (BPAR), graft loss and other adverse events (AEs) associated with everolimus (EVR) and tacrolimus (TAC) exposure…2016 American Transplant Congress
Induction with T-cell Depletional Agents Is Safe and Efficacious in the Very Elderly Kidney Transplant Recipients: An Analysis of the OPTN Database.
Virginia Commonwealth University, Richmond, VA.
Background: Kidney transplantation is increasingly being offered to the very elderly (Age>70 years) kidney transplant recipients. Previous studies analyzing the effect of induction immunosuppression in…2016 American Transplant Congress
Evaluation of the Long-Term Outcomes with Everolimus After Calcineurin Inhibitor Withdrawal: 36M Results of the H2304 and PROTECT Extension Studies.
Background: The H2304 and PROTECT studies demonstrated reduced nephrotoxicity with everolimus (EVR)-based calcineurin inhibitor (CNI; cyclosporine: CsA, tacrolimus: TAC)-free regimens at Month (M) 12. Here,…2016 American Transplant Congress
Reduced CMV Infection Using Single Low-Dose of Rabbit Anti-Thymocyte Globulin in Kidney Transplanted Recipients.
Hospital do Rim - UNIFESP, Sao Paulo, Brazil.
BACKGROUND: Cytomegalovirus (CMV) infection is associated with significant morbidity and mortality after solid organ transplantation and the historic incidence of our institution was 77%. Aiming…2016 American Transplant Congress
Safety, Efficacy, and Cost Saving Potential of Various Weight-Based Dosing for Thymoglobulin Induction Therapy in Kidney Transplant Recipients.
Introduction: There are limited data assessing the appropriate weight to use when dosing Thymoglobulin for induction therapy. The aim of this study is to assess…2016 American Transplant Congress
A Prospective Randomized, Comparative Trial of High-Dose Mizoribine versus Mycophenolate Mofetil in Combination with Tacrolimus and Basiliximab for Living Donor Renal Transplantation: A Multi-Center Trial.
PURPOSE: To compare the clinical outcomes of mizoribine (MZR; 12 mg/kg/day) and mycophenolate mofetil (MMF; 2000 mg/day) in combination with tacrolimus (FK), basiliximab (SIM), and…
American Transplant Congress abstracts